CRISPR Therapeutics AG
GB ˙ LSE
51,84 $ ↓ -4,90 (-8,64%)
2026-06-05
AKTIENPREIS
SecurityGB:0VRQ / CRISPR Therapeutics AG
InstitutionVanguard Group Inc
Latest Disclosed Ownership2,268,394 shares
Latest Disclosed Value $ 118,954,581
Vanguard Group Inc reports 4.07% decrease in ownership of 0VRQ / CRISPR Therapeutics AG

On January 29, 2026 - Vanguard Group Inc filed a 13F-HR form disclosing ownership of 2,268,394 shares of CRISPR Therapeutics AG (GB:0VRQ) valued at $119,709,730 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 7, 2025 disclosing 2,364,645 shares of CRISPR Therapeutics AG. This represents a change in shares of -4.07% during the quarter. The current value of the position is $117,593,545 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-01-29 2025-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,268,394 -96,251 -4.07 118,955 -22.38 0.0017
2025-11-07 2025-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,364,645 66,556 2.90 153,253 37.10 0.0023
2025-08-11 2025-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 2,298,089 528,380 29.86 111,779 85.61 0.0018
2025-05-09 2025-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,769,709 33,711 1.94 60,223 -11.86 0.0011
2025-02-11 2024-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,735,998 10,579 0.61 68,329 -15.71 0.0012
2024-11-13 2024-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,725,419 -23,094 -1.32 81,060 -14.16 0.0015
2024-08-13 2024-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,748,513 111,714 6.83 94,437 -15.35 0.0018
2024-05-10 2024-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,636,799 46,148 2.90 111,564 12.04 0.0022
2024-03-11 2023-12-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,590,651 51,926 3.37 99,575 42.57 0.0022
2024-02-14 2023-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,590,651 51,926 99,575 0.0019
2023-12-18 2023-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,538,725 7,635 0.50 69,843 -18.75 0.0017
2023-11-14 2023-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,538,725 7,635 69,843 0.0003
2023-08-14 2023-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,531,090 46,521 3.13 85,955 28.01 0.0020
2023-07-14 2023-03-31 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 1,484,569 42,292 2.93 67,147 14.53 0.0017
2023-05-15 2023-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,484,569 42,292 67,147 0.0017
2023-02-10 2022-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,442,277 6,867 0.48 58,629 -37.50 0.0016
2022-11-14 2022-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,435,410 112,269 8.49 93,803 16.66 0.0028
2022-08-12 2022-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,323,141 105,852 8.70 80,407 5.23 0.0023
2022-05-13 2022-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 1,217,289 880,463 261.40 76,410 199.35 0.0018
2022-02-14 2021-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 336,826 -23,715 -6.58 25,525 -36.75 0.0006
2021-11-12 2021-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 360,541 96,783 36.69 40,355 -5.49 0.0010
2021-08-13 2021-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 263,758 4,061 1.56 42,700 34.94 0.0011
2021-05-14 2021-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 259,697 9,557 3.82 31,643 -17.38 0.0009
2021-02-12 2020-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 250,140 -140,284 -35.93 38,299 17.28 0.0011
2020-11-16 2020-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 390,424 56,870 17.05 32,655 33.22 0.0011
2020-08-14 2020-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 333,554 147,782 79.55 24,513 211.12 0.0009
2020-05-15 2020-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 185,772 15,637 9.19 7,879 -23.96 0.0003
2020-02-14 2019-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 170,135 88,044 107.25 10,362 207.93 0.0004
2019-11-14 2019-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 82,091 932 1.15 3,365 -11.96 0.0001
2019-08-14 2019-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 81,159 16,821 26.14 3,822 66.32 0.0001
2019-05-15 2019-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 64,338 4,283 7.13 2,298 33.92 0.0001
2019-02-14 2018-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 60,055 8,032 15.44 1,716 -25.62 0.0001
2018-12-13 2018-09-30 13F/A-2 CRISPR THERAPEUTICS NAMEN AKT H17182108 52,023 3,200 6.55 2,307 -19.59 0.0001
2018-11-23 2018-09-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 52,023 0 2,307 0.0001
2018-11-14 2018-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 52,023 3,200 2,307
2018-08-14 2018-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 48,823 7,479 18.09 2,869 51.80 0.0001
2018-05-15 2018-03-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 41,344 24,076 139.43 1,890 366.67 0.0001
2018-02-14 2017-12-31 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 17,268 -15 -0.09 405 31.07 0.0000
2017-11-14 2017-09-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 17,283 264 1.55 309 13.19 0.0000
2017-08-24 2017-06-30 13F/A-1 CRISPR THERAPEUTICS NAMEN AKT H17182108 17,019 17,019 273 0.0000
2017-08-11 2017-06-30 13F CRISPR THERAPEUTICS NAMEN AKT H17182108 17,019 273 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.